Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05605899
Title A Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
Acronym ZUMA-23
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Kite, A Gilead Company
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS

No variant requirements are available.